Ca001-050 - A Randomized, Open-Label Phase 2 Clinical Trial Of Bms-986012 In Combination With Carboplatin, Etoposide, And Nivolumab As First-Line Therapy In Extensive-Stage Small Cell Lung Cancer
Posted Date: Mar 31, 2022
- Investigator: Jennifer Leddon
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
Criteria:
To Be Eligible: Histologically Or Cytologically Documented Extensive-Stage Small Cell Lung Cancer (Es-Sclc) And Extensive-Stage Disease, Must Provide A Fresh Tumor Biopsy From The Primary Disease Site (When Possible) Or From Any Metastatic Site When The P
Keywords:
Lung, Cancer, Phase 2
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com